MannKind Corporation MNKD R2K

Q: What is the current share price of MannKind Corporation (MNKD)?

As of 2026-07-14 21:23 PDT, MannKind Corporation (MNKD) trades at $3.88 on NasdaqGM. Its 52-week range is $2.28 to $6.21.

Q: What is the market capitalisation of MNKD?

MannKind Corporation (MNKD) has a market capitalisation of $1.20B on NasdaqGM.

Q: What is the P/E ratio of MNKD?

MNKD trades at a trailing price-to-earnings (P/E) ratio of -55.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -19.06.

Q: What is the return on equity (ROE) of MNKD?

MNKD has a return on equity (ROE) of -11.49%. Its return on capital employed (ROCE) is 6.25%.

Q: Is MNKD a good stock to buy?

This page provides a data-driven analysis of MannKind Corporation (MNKD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://mannkindcorp.com

Company Profile ↓

$3.88

-3.72% 1Y

Mkt Cap$1.20B

P/E-55.43

P/B-19.06

52W High$6.21

52W Low$2.28

Book Value$-0.19

EPS (TTM)$-0.07

Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 73.1% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $348.97M (+22.2% YoY); net profit $5.86M.
Trailing 12 Months Year-on-year growth — revenue +15.1%, earnings -78.8%.
5-Year Trend Long-term compounding — revenue CAGR 73.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	73.10%
1 Year:	15.10%

Compounded Profit Growth

5 Years:	-
1 Year:	-78.75%

Stock Price Performance

1 Year:	-3.72%
6 Months:	-33.68%
3 Months:	+46.97%
1 Month:	+3.47%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 41% of range

$2.28 $6.21

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)48.21 · Neutral

Price Performance

1M+3.47%

3M+46.97%

6M-33.68%

1Y-3.72%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 73.1% over 5 years.
Generates positive free cash flow.

CONS

Trading 37.5% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-55.43

Industry PE

25.41

Forward P/E

20.16

PEG Ratio

4.39

Book Value

$-0.19

Price to Book

-19.06

P/S

3.13

EV/EBITDA

40.51

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

73.10%

Profit 5Y

Revenue (YoY)

15.10%

Earnings (YoY)

-78.75%

Profitability & Returns

ROCE

6.25%

ROE

-11.49%

ROA

2.03%

Profit Margin

-6.63%

Op Margin

-3.31%

Gross Margin

75.63%

EPS (Latest Qtr)

$-0.05

EPS (TTM)

$-0.07

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

1.43

Current Ratio

1.87

Debt

$434.15M

Total Assets

$744.40M

Current Assets

Working Capital

Ownership

Promoter Holding

1.55%

Chg in Prom Hold

FII / Inst Holding

59.27%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$1.20B

Total Revenue (TTM)

$360.78M

EBITDA

$35.32M

Free Cash Flow

$47.00M

Operating Cash Flow

$19.27M

Shares Outstanding

308.95M

Gross Margin

75.63%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MNKD MannKind Corporation R2K	3.88	-55.43	$1.20B	0.00%	6.25%	-11.49%	73.10%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	3.01M	2.16M	2.04M	4.53M	3.46M	3.89M	4.47M	16.03M	17.45M	15.00M	14.60M	15.99M	16.23M	15.11M	15.35M	17.44M	23.28M	22.21M	11.99M	18.89M	32.83M	40.63M	48.61M	51.25M	66.26M	72.39M	70.08M	78.35M	76.53M	82.13M	90.17M
Operating Income	-	-21.74M	-24.05M	-26.00M	-	-20.01M	-19.12M	118.23M	-	-19.60M	-31.57M	-28.18M	-	-26.79M	-20.54M	-21.54M	-	-13.51M	-10.95M	-8.78M	-	-7.12M	-7.92M	-9.13M	-6.19M	-10.27M	-6.59M	-21.26M	-20.45M	-9.61M	-6.00M	1.72M	5.10M	16.72M	16.61M	12.76M	22.29M	5.30M	18.90M	-1.67M
Net Income	-36.44M	-30.66M	-28.91M	-31.86M	-277.02M	-24.87M	-29.96M	126.52M	53.98M	-16.32M	-35.34M	-32.89M	-32.78M	-30.39M	-22.68M	-24.17M	-9.75M	-14.88M	-12.39M	-10.37M	-14.26M	-9.32M	-10.25M	-11.26M	-12.92M	-35.52M	-4.43M	-26.00M	-29.02M	-14.43M	-9.79M	-5.26M	1.72M	10.63M	-2.01M	11.55M	13.16M	668.00K	7.99M	-16.62M
Diluted EPS	-	-	-	-0.08	-	-0.29	-0.33	1.31	0.56	-0.17	-0.35	-0.31	-0.28	-0.25	-0.16	-0.16	-0.06	-	-	-	-	-	-	-	-	-0.14	-0.02	-0.10	-0.11	-0.06	-0.04	-0.02	0.01	0.04	-0.01	0.04	0.04	0.00	0.03	-0.05

Profit & Loss (Annual)

Figures in USD.

Metric	Feb 1992	Feb 1993	Feb 1994	Dec 1994	Dec 1995	Dec 1996	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93.00K	50.00K	35.00K	0	0	0	174.76M	11.74M	27.86M	63.04M	65.14M	75.44M	99.77M	198.96M	285.50M	348.97M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-209.78M	-152.50M	-140.54M	-146.96M	-169.40M	-179.63M	-344.65M	67.26M	-108.19M	-76.59M	-44.60M	-47.91M	-47.02M	-64.11M	8.68M	72.59M	38.80M
Net Income	-911.00K	-1.18M	-1.16M	-2.00M	-2.81M	-2.57M	-2.28M	-3.33M	-5.68M	-24.66M	-48.24M	-206.26M	-65.88M	-75.99M	-114.34M	-230.55M	-293.19M	-303.04M	-220.10M	-170.56M	-160.80M	-169.37M	-191.49M	-198.38M	-368.44M	125.66M	-117.33M	-86.97M	-51.90M	-57.24M	-80.93M	-87.40M	-11.94M	27.59M	5.86M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.57	-4.54	1.36	-1.13	-0.60	-	-0.26	-0.32	-0.34	-0.04	0.10	0.02

Balance Sheet (Annual)

Figures in USD.

Metric	Feb 1992	Feb 1993	Feb 1994	Dec 1994	Dec 1995	Dec 1996	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	277.26M	199.55M	251.31M	258.65M	394.44M	126.41M	107.06M	84.58M	107.70M	93.72M	108.61M	321.16M	295.28M	475.20M	393.84M	792.18M
Total Equity	-11.00K	-278.00K	-908.00K	-707.00K	-3.11M	-5.48M	-7.37M	3.40M	-746.00K	31.89M	235.02M	90.77M	111.58M	150.36M	206.98M	383.49M	364.10M	86.73M	-59.22M	-185.53M	-313.65M	-110.68M	-30.71M	-73.77M	-350.33M	-183.59M	-214.73M	-175.08M	-190.53M	-180.42M	-209.35M	-250.54M	-246.17M	-78.82M	-51.02M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.65M	30.02M	66.06M	2.68M	61.84M	70.79M	120.84M	59.07M	22.89M	43.95M	71.16M	29.91M	67.00M	124.18M	69.77M	238.48M	46.34M	74.88M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	102.49M	118.90M	122.23M	281.20M	273.49M	268.70M	36.05M	354.64M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	462.79M	513.21M	361.99M	289.36M	468.21M	476.74M	290.66M	299.31M	282.79M	284.25M	289.03M	530.51M	545.82M	721.37M	472.66M	843.20M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18.13M	25.36M	144.78M	127.79M	403.35M	268.32M	92.05M	87.60M	75.24M	65.62M	73.70M	48.35M	67.30M	104.12M	81.84M	171.03M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-184.08M	-148.65M	-123.84M	-119.86M	-128.73M	-	-	-78.09M	-64.78M	-37.73M	-88.48M	-28.13M	-61.71M	-80.68M	34.09M	42.51M	18.25M
Investing Cash Flow	-3.05M	-11.72M	-2.94M	-560.00K	-7.99M	-	-	-1.13M	16.68M	-234.00K	-22.84M	15.22M	-151.54M	4.87M	-1.99M	-96.65M	-304.80M
Financing Cash Flow	189.51M	196.42M	63.39M	179.58M	145.67M	-	-	43.04M	73.56M	61.29M	69.86M	49.85M	270.27M	21.39M	136.61M	-137.27M	315.10M
Capital Expenditure	-18.85M	-9.54M	-6.86M	-637.00K	-7.99M	-24.10M	-10.29M	-1.14M	-	-354.00K	-2.56M	-801.00K	-11.47M	-7.59M	-42.44M	-9.69M	-4.57M
Free Cash Flow	-202.94M	-158.20M	-130.69M	-120.50M	-136.72M	-	-	-79.23M	-	-38.09M	-91.05M	-28.93M	-73.17M	-88.27M	-8.35M	32.82M	13.69M

Ratios (Annual)

Figures in %.

Metric	Feb 1992	Feb 1993	Feb 1994	Dec 1994	Dec 1995	Dec 1996	Dec 1997	Dec 1998	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-163,976.3%	-281,078.0%	-419,885.7%	-	-	-	38.5%	-921.1%	-274.9%	-70.7%	-73.5%	-62.3%	-64.3%	4.4%	25.4%	11.1%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-183,397.8%	-321,608.0%	-483,902.9%	-	-	-	71.9%	-999.0%	-312.2%	-82.3%	-87.9%	-107.3%	-87.6%	-6.0%	9.7%	1.7%
ROE %	8,281.8%	422.7%	127.3%	283.5%	90.6%	46.9%	30.9%	-97.9%	761.3%	-77.3%	-20.5%	-227.2%	-59.0%	-50.5%	-55.2%	-60.1%	-80.5%	-349.4%	371.7%	91.9%	51.3%	153.0%	623.5%	268.9%	105.2%	-68.4%	54.6%	49.7%	27.2%	31.7%	38.7%	34.9%	4.8%	-35.0%	-11.5%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-58.9%	-80.7%	-137.9%	-129.5%	2,015.1%	242.9%	448.0%	3,580.0%	-235.9%	-158.7%	-137.3%	-17.2%	-28.1%	2.3%	23.3%	6.2%

Shareholding Pattern

Insiders

1.55%

Institutions

59.27%

Public Float

60.20%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.26%	28.60M	$126.12M
2	State Street Corporation	6.05%	18.68M	$82.38M
3	Vanguard Capital Management LLC	4.17%	12.89M	$56.84M
4	UBS Group AG	2.67%	8.26M	$36.40M
5	Geode Capital Management, LLC	2.43%	7.51M	$33.09M
6	Millennium Management Llc	2.07%	6.39M	$28.18M
7	Frazier Life Sciences Management, L.P.	1.91%	5.90M	$26.02M
8	Morgan Stanley	1.88%	5.79M	$25.54M
9	Dimensional Fund Advisors LP	1.60%	4.95M	$21.84M
10	180 Wealth Advisors, LLC	1.39%	4.29M	$18.92M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MNKD

Google News Mon, 29 Jun 2026

Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQeE4zZ0lYdFdCdTRQQmg3VEtNZzNSR0FNbG9NWkxUTVJfdW01ZlNDdUgyczV5b1V4WjBxY0FiZFdWVFNsZ0ROdmFWcVc3SGN0LVlZNmZFeEljdm1faGxoWElzM0VpcDNaMjhQMG1FdEdGME15ejROQlRwN1p1cE0yRGFSVWNaY0hIOURyaG…

Google News ue, 23 Jun 2026

Breakthrough T1D backs MannKind’s pediatric Afrezza trial - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxONUZDellQOV9Bb3VXTjRQOURoY2FHS05Tb3V2UzZsMVBDMlRfdXpXZF9tMUNFSW43eHVCeHRKVy15UU9lVXZDOEhSblFVUlFySGFXMW9NRXBQRi1KdnF2a2VyYk0xdUxNRHFGUU9uQmZXaHlzTTZqalNpUEEtc2t0RHFMSkR5QmFjbGQtQ0…

Google News Fri, 03 Jul 2026

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxQX2cyYnVaVExIWG1QRjNUMVdkQ1Y2eW5VRzJ2WE13ckJXenVLV3F6ZFR4SEcyR2lsc2pveERra0ZxV3ZUUDZTNndrcXZ3aXFGenRmUkZacnM2THRPaTZ2dXdQR3k5ZDh6Q3dpUEV5cll0cUw3c1o2bTZmX2hvXzJkZEhaeDAxYV9id2hodT…

Google News ue, 30 Jun 2026

MNKD Stock Price, Quote & Chart - ChartMill

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5fTjFPbjFJWFB0cVZhOGpIMWxRbHlOY3pWeVJHdGQtUUhseENzbWNNX0EtZmlqWnJhaEtsaS1TQlNFVXZpZGFqMnV0cmxYbERCT1BiS0dERzIzS3M1ZURR?oc=5" target="_blank">MNKD Stock Price, Quote & Chart</a>&nbs…

Google News hu, 11 Jun 2026

MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOaVVRTU81Wm1HX1d2cU5BY095Qk00WFFsT2lRdjVFV1FFOEpXbzJBZEgzc2xPUHV5amRfQ3JwNGJZWWp0SEk0LVFZeWsybmtncGc0cXUxRi1GWjU0VmZMZFluNEFBakJza2ZhOWZCaHlEd3ZvUlJwX3VCd0J1SFMxU1lvUTJXVVllRFFhbU…

Google News ue, 05 May 2026

Stocks Facing FDA Decision In May—MannKind (MNKD) - Forbes

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPblNOZlA2T2pvZUlrV3J2WlAxYTFrcWpEUkFQbTVXWGhRWjlZQldCdzVJakR2ZzFodF9pMTFTaUt6YmtUMVY4UnJOOFp0bm1OSm9WWHl6R19IekswRkNSd2tib2xCNHJCQkJiYlhfSVNQSlFodHQtLTBCR0V6ZXB0MUk0Q3FhSkF6OUJ0Wj…

MNKD — Frequently Asked Questions

What is the current share price of MannKind Corporation (MNKD)?

As of 2026-07-14 21:23 PDT, MannKind Corporation (MNKD) trades at $3.88 on NasdaqGM. Its 52-week range is $2.28 to $6.21.

What is the market capitalisation of MNKD?

MannKind Corporation (MNKD) has a market capitalisation of $1.20B on NasdaqGM.

What is the P/E ratio of MNKD?

MNKD trades at a trailing price-to-earnings (P/E) ratio of -55.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is -19.06.

What is the return on equity (ROE) of MNKD?

MNKD has a return on equity (ROE) of -11.49%. Its return on capital employed (ROCE) is 6.25%.

Is MNKD a good stock to buy?

This page provides a data-driven analysis of MannKind Corporation (MNKD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

MannKind Corporation MNKD R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Is MannKind Corporation (MNKD) A Good Stock To Buy Now? - Yahoo Finance

Breakthrough T1D backs MannKind’s pediatric Afrezza trial - Stock Titan

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

MNKD Stock Price, Quote & Chart - ChartMill

MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance

Stocks Facing FDA Decision In May—MannKind (MNKD) - Forbes

MNKD — Frequently Asked Questions

What is the current share price of MannKind Corporation (MNKD)?

What is the market capitalisation of MNKD?

What is the P/E ratio of MNKD?

What is the return on equity (ROE) of MNKD?

Is MNKD a good stock to buy?

Explore More